Company News

IMM2902 of ImmuneOnco Completed the First Patient Dosing

February 15, 2022, Shanghai, China.  ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco", the company) announced that the first bispecific antibody-receptor recombinant protein (project number: IMM2902) targeting human CD47 x HER2 has completed the first patient enrollment and dosing, and administration process was smooth and successful.  

IMM2902, a CD47xHER2 bispecific fusion protein designed for solid tumors, is at the forefront of global research. The project has previously been approved by the National Medical Products Administration (NMPA) and the US Food and Drug Administration (FDA) for clinical trials on June 29, 2021 and August 21, 2021. It is the third new drug project in the clinical research stage of the company based on targeting CD47/SIRPa. The completion of the first subject enrollment and dosing in the IMM2902 project is another major milestone for the company.

Dr. Wenzhi Tian, Founder and CEO of the company, is very confident in the clinical trial research of IMM2902.

"We are very pleased that our IMM2902 project has completed the first patient in. IMM2902 is a bispecific molecule developed on our mAb-Trap technique platform for CD47 and HER2. The molecule preferentially binds to tumor cells through the high affinity to HER2 and CD47, at the same time, it doesn’t bind to human red blood cells and other off-target cells, so as to avoid the "Antigen sink” effect, thereby greatly enhance the synergistic effect based on both targets against tumors. IMM2902 will have great potential in clinical development and commercial value.”